Eye - subfoveal choroidal neovascularisation

The PBS subsidises aflibercept and ranibizumab for patients with subfoveal choroidal neovascularisation (CNV).

Patient eligibility

The PBS subsidises treatment with aflibercept and ranibizumab under the National Health Act 1953, Section 85 for patients with subfoveal CNV.

Patients must be eligible for the PBS and meet the relevant restriction criteria.

The Schedule of Pharmaceutical Benefits outlines the restrictions for prescribing aflibercept and ranibizumab.

Treatment specifics

To be eligible for PBS subsidised treatment with these medications, patients must be treated by:

  • an ophthalmologist
  • an accredited ophthalmology registrar in consultation with an ophthalmologist.

Authority applications

Applying for initial treatment

Apply for authority approval to prescribe initial PBS subsidised aflibercept and ranibizumab in writing and either:

All applications must include the completed:

Applications to move between different drugs to treat CNV will require a new initial authority application to be completed.

Applying for continuing treatment

Applications for continuing authority applications to prescribe PBS subsidised aflibercept and ranibizumab can be made either:

Further information

Call the PBS Complex Drugs Programs enquiry line for further information.

Page last updated: 1 October 2020